Hygeia Hospital Adopts RTsafe Technology to Enhance Patient-specific Safety in Brain Cancer Radiotherapy
Athens, Greece – November 27, 2018 - RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, today announced that Hygeia Hospital adopted RTsafe’s Personalized PseudoPatient™ technology to enhance patient safety in brain cancer radiotherapy.
Since 1970, Hygeia Hospital provides top-quality medical services in Greece and in Europe, and is among recognized leading institutions worldwide. The hospital’s priority is to continue to offer top-level healthcare services and adopt all the latest technology in medical science, including radiation oncology, while following strict quality policy that safeguards patient safety. Hygeia turned to RTsafe for its unique approach to quality assurance which significantly enhances the safety and efficiency of radiotherapy for cancer, especially when advanced radiotherapy applications, such as stereotactic radiosurgery, are used.
Radiation therapy is commonly applied for brain cancer treatment but it’s a highly complex process. On one hand, there is a desire to seek out and destroy all cancer cells. On the other hand, directly alongside a brain tumor there is healthy tissue that should be preserved. Inevitably, there will be many cases where a dose of radiation just millimeters beyond its intended site can have far-reaching physiological impact. Ensuring the safety of each patient is critical. Which is why Hygeia adopted RTsafe’s Personalized PseudoPatient™, an FDA cleared medical technology that enables radiotherapy professionals for the first time to safely simulate and verify an individual treatment cycle before exposing the actual patient to potentially harmful radiation. This partnership also places Hygeia at the forefront of radiotherapy for brain cancer as the first hospital in Southeastern Europe to use RTsafe’s Personalized PseudoPatient™ head phantoms for patient-specific pre-treatment plan verification.
Hygeia Hospital applies a series of procedures to guarantee the quality and safety of its patient treatments. “The implementation of end-to-end quality assurance using RTsafe’s Personalized PseudoPatient™ is a big step toward individualized quality assurance in radiotherapy and provides the most innovative medical technology today on this issue”, said Konstantinos Dardoufas, Director of the Hygeia Radiation Oncology Center. “Our initial experience with RTsafe’s technology is very promising because it enhances the confidence of our medical staff and cancer patients that their radiation treatment plan is safe.”
“Our partnership with Hygeia validates the pressing need for personalized medicine in radiation oncology”, said RTsafe’s CEO, Dr. Evangelos Pappas. “We’re thrilled that such a highly-regarded hospital has adopted RTsafe’s solution in an effort to provide the most advanced technology available for ensuring patient safety in radiotherapy and radiosurgery.”
RTsafe’s Personalized PseudoPatient™ is the world’s first personalized pre-treatment simulation system for quality assurance in radiation oncology. At the heart of the concept is an anatomically authentic head phantom of individual patients suffering from brain tumors. Using each patient’s anonymized CT scan, and deploying highly accurate medical grade 3D-printing technology and the latest dosimetry methodologies, RTsafe can create a patient-specific phantom which reacts to radiation in the exact same way that human tissue does. It is a perfect replica of the real patient’s head and bone structure, both externally and internally. RTsafe’s technology currently has a granted patent by the European Patent Office and published patent applications in several other countries globally.
Given the critical importance of accuracy in brain radiotherapy, Hygeia’s patients can now be reassured that their own treatment can be simulated and verified in a totally safe environment before they are exposed to radiation. The hospital has already used RTsafe’s technology to verify the radiation treatment of a number of pediatric and adult patients.
RTsafe is a medical technology company that has developed a unique approach to quality assurance that significantly enhances the safety and accuracy of radiotherapy for cancer and other medical conditions. It combines proven expertise in medical physics with highly accurate 3D printing technology to create pseudo‐in‐vivo dosimetry phantoms towards End‐to‐End commissioning, benchmarking and patient‐specific quality assurance in SRS, IMRT, VMAT and SBRT applications. The anatomically accurate effigies enable medical professionals to plan more precise treatment interventions for each individual patient and help radiotherapy technology innovators to fine‐tune their products. The result is more effective individualized therapy and reduced patient risk. For more information, visit www.rt-safe.com.
Dr. Evangelos Pappas